EUVIMEDEUVIMED entdecken
Crossref

Non‐Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual‐Pathway T Cell Activation

Xiaoyuan Fan, Fengxiang Liu, Qing You, Yiyang Wang, Lili Du, Xinpeng Zou, Fei Sun, Lianwen Qi iD, Zhonggui He iD, Jin Sun iD, Shujun Wang, Liang Sang und 1 weitere

Advanced Materials · 2026-06 · 38 (32)

DOI: 10.1002/adma.73231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 01.05.2026. Verfasst von Xiaoyuan Fan und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Cancer Vaccines, Lymphocyte Activation, Nanovaccines, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Liaoning Province Applied Basic Research Program, Liaoning Revitalization Talents Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The therapeutic efficacy of cancer vaccines is critically contingent upon CD8 + T cell‐mediated antitumor immunity, but the effectiveness is hindered due to insufficient T cell activation. Inspired by the close interplay between cellular physiological states and immunoregulatory functions, we propose ASCENT, a nanovaccine platform integrating nanovesicles derived from activated platelets and senescent tumor cells to naturally co‐present antigens and co‐stimulatory molecules, thereby enabling dual‐pathway T cell activation. Specifically, senescent tumor cells promote antigen presentation via upregulated major histocompatibility complex‐I (MHC‐I) molecules, whereas activated platelets increase the surface expression of CD40L and OX40L, thereby enhancing immune activation. Thus, without genetic or chemical engineering, ASCENT can effectively stimulate CD8 + T cells through both antigen self‐presentation and dendritic cell‐mediated antigen presentation, ultimately eliciting robust immune responses. This non‐engineered, physiologically modulated nanovaccine exhibits broad‐spectrum antitumor activity while simultaneously inducing durable systemic immune memory to effectively suppress tumor recurrence and metastasis. Overall, the ASCENT nanovaccine provides new perspectives on rational vaccine design, emphasizing the importance of engaging both direct and indirect T cell activation in reinforcing cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesLymphocyte ActivationNanovaccinesNeoplasmsT-LymphocytesAnimalsHumansAntigen PresentationCD8-Positive T-LymphocytesDendritic Cells

Stichwörter der Autor:innen

activated platelet‐induced co‐stimulatory molecule presentationcancer vaccinesdual‐pathway T cell activationphysiologically modulated nanovesiclessenescent tumor cell‐enhanced antigen display

Substanzen

Cancer VaccinesNanovaccines

Autor:innen und Institutionen

  • School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
  • Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, China.
  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, China.
  • Joint International Research Laboratory of Intelligent Drug Delivery Systems, Ministry of Education, Shenyang, China.

ORCID-Profile: Lianwen Qi, Zhonggui He, Jin Sun, Kaiyuan Wang

Förderung

  • National Natural Science Foundation of China
  • Liaoning Province Applied Basic Research Program
  • Liaoning Revitalization Talents Program
  • Prospective Basic research project of 2024 Scientific Research Project of Liaoning Department of Education

Zitieren

APA

Fan, X., Liu, F., You, Q., Wang, Y., Du, L., Zou, X., Sun, F., Qi, L., He, Z., Sun, J., Wang, S., Sang, L., & Wang, K. (2026). Non‐Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual‐Pathway T Cell Activation. Advanced Materials, 38(32). https://doi.org/10.1002/adma.73231

Vancouver

Fan X, Liu F, You Q, Wang Y, Du L, Zou X, et al. Non‐Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual‐Pathway T Cell Activation. Advanced Materials. 2026;38(32). doi:10.1002/adma.73231

BibTeX
@article{Fan2026,
  author = {Fan, Xiaoyuan and Liu, Fengxiang and You, Qing and Wang, Yiyang and Du, Lili and Zou, Xinpeng and Sun, Fei and Qi, Lianwen and He, Zhonggui and Sun, Jin and Wang, Shujun and Sang, Liang and Wang, Kaiyuan},
  title = {Non‐Engineered Physiologically Modulated Nanovesicles Augment Antitumor Immune Responses via Dual‐Pathway T Cell Activation},
  journal = {Advanced Materials},
  year = {2026},
  volume = {38},
  number = {32},
  doi = {10.1002/adma.73231}
}
Kostenlos starten →